Draupnir Bio • About
Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society. We are establishing ourselves at the forefront of protein degradation. At Draupnir, our differentiated platform technology is enabling the development of protein degraders that target extracellular disease proteins, with potential to target 40% of the human proteome and offering broad disease applicability across multiple areas of unmet therapeutic need. Our team at Draupnir Bio is driven by a deep commitment to scientific excellence, and by the desire to bring innovative therapies to patients. Draupnir Bio is a spin out from Aarhus University and the Max-Planck Society based on the breakthrough scientific findings of Professors Simon Glerup, Camilla Gustafsen, Peder Søndergaard Madsen, and Peter Seeberger. Draupnir Bio expands research operations with new R&D facility at INCUBA research park. Draupnir Bio funded by a 30 M EUR series A investment by Novo Seeds, Gilde Healthcare Partners, INKEF Capital and High-Tech Gründerfonds. Draupnir Bio founded with investment from founders and grant from the Novo Nordisk Foundation.
Keywords
Industries
Where is Draupnir Bio located?
The company Draupnir Bio is located in Copenhagen, Capital Region of Denmark, Denmark. It's worth noting that the company may has more corporate locations
How many employees does Draupnir Bio approximately have?
As of the latest available information Draupnir Bio has around 11-50 employees worldwide.
When was Draupnir Bio founded?
Draupnir Bio was founded in 2017
In which industries does Draupnir Bio mainly work?
The company Draupnir Bio has it's main focus in the industries of Biotechnology